Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15741132 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2 | |
| SCHEMBL21028738 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2 | |
| SCHEMBL24029638 | 0.94 | SLC5A1 (0.88) | SLC5A1SLC5A2 | |
| SCHEMBL24029894 | 0.92 | SLC5A1 (0.86) | SLC5A1SLC5A2 | |
| SCHEMBL24029872 | 0.92 | SLC5A1 (0.85) | SLC5A1SLC5A2 | |
| SCHEMBL24029784 | 0.92 | SLC5A1 (0.85) | SLC5A1SLC5A2 | |
| SCHEMBL20787290 | 0.92 | SLC5A1 (0.84) | SLC5A1SLC5A2 | |
| SCHEMBL24030058 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2 | |
| SCHEMBL24029588 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2 | |
| SCHEMBL26806263 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724429-A1 | SGLT1 INHIBITOR AND INCRETIN COMBINATIONS FOR TREATING METABOLIC DISEASE | Vogenx (US) | 2026-04-15 | — | — | EP | claimed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| US-20250170157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | LEXICON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2025101731-A1 | SGLT1 INHIBITORS FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | LEXICON PHARMACEUTICALS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2024254352-A1 | SGLT1 INHIBITOR AND INCRETIN COMBINATIONS FOR TREATING METABOLIC DISEASE | VOGENX (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2024-07-04 | — | — | US | claimed |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2023-06-15 | — | — | US | claimed |
| US-11596644-B2 | Method for treating post-prandial hypoglycemia | AVOLYNT (US) | 2023-03-07 | — | — | US | claimed |
| US-20220257624-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | VOGENX | 2022-08-18 | — | — | US | claimed |
| EP-3976053-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | Avolynt (US) | 2022-04-06 | — | — | EP | claimed |
| US-12612426-B2 | Aryl glucoside derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12612427-B2 | Aryl glucoside derivative, preparation method therefor and application thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12522628-B2 | Aryl glucoside derivative and use thereof in drug | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-108026153-B | Novel exendin-4 derivatives as selective peptide dual GLP-1/glucagon receptor agonists | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| US-20220153772-A1 | GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20220143003-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. | 2022-05-12 | — | — | US | disclosed |
| CN-114423775-A | Aryl glucoside derivatives, and preparation method and application thereof | 上海喆邺生物科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022063305-A1 | CRYSTAL FORM OF GLUCOSIDE COMPOUNDS AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612426-B2 | Aryl glucoside derivative | SLC5A1, SLC5A2, GPR119 | SLC5A1 1/4885SLC5A2 2/4885 |
| US-20220153772-A1 | GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF | SLC5A1, SLC5A2, UGGT1 | SLC5A1 1/4885SLC5A2 2/4885 |
| US-11596644-B2 | Method for treating post-prandial hypoglycemia | SLC5A1, SLC5A2, GLP1R | SLC5A1 1/4885SLC5A2 2/4885 |
| US-12612427-B2 | Aryl glucoside derivative, preparation method therefor and application thereof | SLC5A1, SLC10A1, SLC5A2 | SLC5A1 1/4885SLC5A2 3/4885 |
| US-20250170157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | OAT, GYS2, OTC | SLC5A1 1660/4885SLC5A2 1324/4885 |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | SLC5A1, CFTR, SLC5A2 | SLC5A1 1/4885SLC5A2 3/4885 |
| US-20220257624-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | SLC5A2, SLC5A1, SLC10A1 | SLC5A1 2/4885SLC5A2 1/4885 |
| US-20220143003-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | GLP1R, SLC5A1, SLC5A2 | SLC5A1 2/4885SLC5A2 3/4885 |
| US-20230181610-A1 | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | SLC5A1, CFTR, SLC5A2 | SLC5A1 1/4885SLC5A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.